

Lorenzo Galluzzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8262102/publications.pdf>

Version: 2024-02-01

476
papers

86,369
citations

558

126
h-index

394

279
g-index

483
all docs

483
docs citations

483
times ranked

90751
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
3	Mitochondrial Membrane Permeabilization in Cell Death. Physiological Reviews, 2007, 87, 99-163.	28.8	3,126
4	Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death and Differentiation, 2009, 16, 3-11.	11.2	2,572
5	Immunogenic Cell Death in Cancer Therapy. Annual Review of Immunology, 2013, 31, 51-72.	21.8	2,489
6	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and Differentiation, 2012, 19, 107-120.	11.2	2,144
7	Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31, 1869-1883.	5.9	2,058
8	Immunogenic cell death in cancer and infectious disease. Nature Reviews Immunology, 2017, 17, 97-111.	22.7	2,000
9	Molecular mechanisms of necroptosis: an ordered cellular explosion. Nature Reviews Molecular Cell Biology, 2010, 11, 700-714.	37.0	1,941
10	Targeting mitochondria for cancer therapy. Nature Reviews Drug Discovery, 2010, 9, 447-464.	46.4	1,389
11	Molecular definitions of autophagy and related processes. EMBO Journal, 2017, 36, 1811-1836.	7.8	1,230
12	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell, 2015, 28, 690-714.	16.8	1,205
13	Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice. Science, 2011, 334, 1573-1577.	12.6	1,159
14	Mechanisms of cytochrome c release from mitochondria. Cell Death and Differentiation, 2006, 13, 1423-1433.	11.2	1,028
15	Regulation of autophagy by cytoplasmic p53. Nature Cell Biology, 2008, 10, 676-687.	10.3	1,025
16	Autophagy in malignant transformation and cancer progression. EMBO Journal, 2015, 34, 856-880.	7.8	1,012
17	Mitochondria and the Autophagy-Inflammation-Cell Death Axis in Organismal Aging. Science, 2011, 333, 1109-1112.	12.6	983
18	Acetyl Coenzyme A: A Central Metabolite and Second Messenger. Cell Metabolism, 2015, 21, 805-821.	16.2	963

#	ARTICLE	IF	CITATIONS
19	Macrophages and Metabolism in the Tumor Microenvironment. <i>Cell Metabolism</i> , 2019, 30, 36-50.	16.2	933
20	Type I interferons in anticancer immunity. <i>Nature Reviews Immunology</i> , 2015, 15, 405-414.	22.7	929
21	Mitochondrial metabolism and cancer. <i>Cell Research</i> , 2018, 28, 265-280.	12.0	818
22	Decoding cell death signals in liver inflammation. <i>Journal of Hepatology</i> , 2013, 59, 583-594.	3.7	755
23	Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. <i>Immunity</i> , 2013, 39, 74-88.	14.3	739
24	Metabolic Control of Autophagy. <i>Cell</i> , 2014, 159, 1263-1276.	28.9	703
25	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 725-741.	27.6	701
26	Cell death modalities: classification and pathophysiological implications. <i>Cell Death and Differentiation</i> , 2007, 14, 1237-1243.	11.2	688
27	Consensus guidelines for the detection of immunogenic cell death. <i>Oncotmunology</i> , 2014, 3, e955691.	4.6	686
28	Mitotic catastrophe: a mechanism for avoiding genomic instability. <i>Nature Reviews Molecular Cell Biology</i> , 2011, 12, 385-392.	37.0	682
29	Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 487-511.	46.4	642
30	Autophagy in major human diseases. <i>EMBO Journal</i> , 2021, 40, e108863.	7.8	615
31	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
32	Mitochondria: master regulators of danger signalling. <i>Nature Reviews Molecular Cell Biology</i> , 2012, 13, 780-788.	37.0	601
33	Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. <i>Cell Death and Differentiation</i> , 2009, 16, 1093-1107.	11.2	599
34	Metabolic targets for cancer therapy. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 829-846.	46.4	592
35	The secret ally: immunostimulation by anticancer drugs. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 215-233.	46.4	591
36	Metabolic Control of Longevity. <i>Cell</i> , 2016, 166, 802-821.	28.9	591

#	ARTICLE	IF	CITATIONS
37	Autophagy-Independent Functions of the Autophagy Machinery. <i>Cell</i> , 2019, 177, 1682-1699.	28.9	591
38	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. <i>Immunity</i> , 2013, 38, 729-741.	14.3	572
39	Autophagy and Mitophagy in Cardiovascular Disease. <i>Circulation Research</i> , 2017, 120, 1812-1824.	4.5	559
40	Control of Metastasis by NK Cells. <i>Cancer Cell</i> , 2017, 32, 135-154.	16.8	549
41	Metabolic control of cell death. <i>Science</i> , 2014, 345, 1250256.	12.6	527
42	Inflammasomes in carcinogenesis and anticancer immune responses. <i>Nature Immunology</i> , 2012, 13, 343-351.	14.5	525
43	Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. <i>Cell Death and Disease</i> , 2010, 1, e10-e10.	6.3	518
44	Cell death assays for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 221-237.	46.4	482
45	Necroptosis: A Specialized Pathway of Programmed Necrosis. <i>Cell</i> , 2008, 135, 1161-1163.	28.9	475
46	Detection of immunogenic cell death and its relevance for cancer therapy. <i>Cell Death and Disease</i> , 2020, 11, 1013.	6.3	466
47	Necroptosis: Mechanisms and Relevance to Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 103-130.	22.4	458
48	Autophagy regulation by p53. <i>Current Opinion in Cell Biology</i> , 2010, 22, 181-185.	5.4	450
49	Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. <i>Journal of Cell Biology</i> , 2011, 192, 615-629.	5.2	439
50	Mitochondrial Control of Cellular Life, Stress, and Death. <i>Circulation Research</i> , 2012, 111, 1198-1207.	4.5	435
51	Immunogenic cell stress and death. <i>Nature Immunology</i> , 2022, 23, 487-500.	14.5	434
52	The hallmarks of successful anticancer immunotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	419
53	Role of the c subunit of the F ₁ F ₀ ATP synthase in mitochondrial permeability transition. <i>Cell Cycle</i> , 2013, 12, 674-683.	2.6	416
54	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	1.8	395

#	ARTICLE	IF	CITATIONS
55	Viral Control of Mitochondrial Apoptosis. PLoS Pathogens, 2008, 4, e1000018.	4.7	379
56	Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nature Medicine, 2021, 27, 212-224.	30.7	376
57	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. Science, 2012, 337, 1678-1684.	12.6	367
58	Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. Science Translational Medicine, 2012, 4, 143ra99.	12.4	367
59	Mitochondrial membrane permeabilization in neuronal injury. Nature Reviews Neuroscience, 2009, 10, 481-494.	10.2	360
60	Autophagy and Cellular Immune Responses. Immunity, 2013, 39, 211-227.	14.3	359
61	Cancer and the gut microbiota: An unexpected link. Science Translational Medicine, 2015, 7, 271ps1.	12.4	358
62	Anti- and pro-tumor functions of autophagy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 1524-1532.	4.1	330
63	Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene, 2006, 25, 4812-4830.	5.9	324
64	Linking cellular stress responses to systemic homeostasis. Nature Reviews Molecular Cell Biology, 2018, 19, 731-745.	37.0	320
65	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	4.8	317
66	The spectrum of T cell metabolism in health and disease. Nature Reviews Immunology, 2018, 18, 19-34.	22.7	315
67	Combinatorial Strategies for the Induction of Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 187.	4.8	289
68	Caspases Connect Cell-Death Signaling to Organismal Homeostasis. Immunity, 2016, 44, 221-231.	14.3	279
69	The IKK complex contributes to the induction of autophagy. EMBO Journal, 2010, 29, 619-631.	7.8	274
70	Natural and therapy-induced immunosurveillance in breast cancer. Nature Medicine, 2015, 21, 1128-1138.	30.7	268
71	Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle, 2008, 7, 3056-3061.	2.6	262
72	miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death. Cancer Research, 2010, 70, 1793-1803.	0.9	262

#	ARTICLE	IF	CITATIONS
73	Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 247-258.	27.6	261
74	DNA Damage in Stem Cells. <i>Molecular Cell</i> , 2017, 66, 306-319.	9.7	259
75	The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. <i>Cell Death and Differentiation</i> , 2009, 16, 1006-1017.	11.2	258
76	To Die or Not to Die: That is the Autophagic Question. <i>Current Molecular Medicine</i> , 2008, 8, 78-91.	1.3	253
77	Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 61-69.	5.9	250
78	First oncolytic virus approved for melanoma immunotherapy. <i>Oncolmunology</i> , 2016, 5, e1115641.	4.6	247
79	Mitochondrial gateways to cancer. <i>Molecular Aspects of Medicine</i> , 2010, 31, 1-20.	6.4	239
80	Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR Activity. <i>Molecular Cell</i> , 2012, 48, 667-680.	9.7	239
81	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmunology</i> , 2015, 4, e1008866.	4.6	237
82	The autophagic network and cancer. <i>Nature Cell Biology</i> , 2018, 20, 243-251.	10.3	233
83	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmunology</i> , 2014, 3, e957994.	4.6	223
84	No death without life: vital functions of apoptotic effectors. <i>Cell Death and Differentiation</i> , 2008, 15, 1113-1123.	11.2	221
85	Senescence, Apoptosis or Autophagy?. <i>Gerontology</i> , 2008, 54, 92-99.	2.8	220
86	Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. <i>Nature Immunology</i> , 2020, 21, 120-134.	14.5	218
87	Regulation of autophagy by stress-responsive transcription factors. <i>Seminars in Cancer Biology</i> , 2013, 23, 310-322.	9.6	215
88	Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. <i>Nature Immunology</i> , 2020, 21, 1160-1171.	14.5	214
89	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. <i>Oncolmunology</i> , 2017, 6, e1386829.	4.6	209
90	Molecular mechanisms of regulated necrosis. <i>Seminars in Cell and Developmental Biology</i> , 2014, 35, 24-32.	5.0	206

#	ARTICLE	IF	CITATIONS
91	Trial watch. Oncoimmunology, 2012, 1, 1323-1343.	4.6	203
92	Organelle-specific initiation of cell death. Nature Cell Biology, 2014, 16, 728-736.	10.3	198
93	Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 803-813.	4.9	196
94	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology, 2012, 1, 894-907.	4.6	194
95	Cytosolic DNA Sensing in Organismal Tumor Control. Cancer Cell, 2018, 34, 361-378.	16.8	191
96	Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. Nature Reviews Cardiology, 2019, 16, 33-55.	13.7	188
97	Trial Watch. Oncoimmunology, 2012, 1, 699-739.	4.6	184
98	Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene, 2008, 27, 4221-4232.	5.9	183
99	Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging, 2009, 1, 961-970.	3.1	180
100	Crosstalk between ER stress and immunogenic cell death. Cytokine and Growth Factor Reviews, 2013, 24, 311-318.	7.2	177
101	Organelle-Specific Initiation of Autophagy. Molecular Cell, 2015, 59, 522-539.	9.7	176
102	Trial watch. Oncoimmunology, 2013, 2, e24612.	4.6	175
103	Autophagy in acute brain injury. Nature Reviews Neuroscience, 2016, 17, 467-484.	10.2	174
104	Calreticulin and cancer. Cell Research, 2021, 31, 5-16.	12.0	174
105	Mitochondrial Permeability Transition: New Findings and Persisting Uncertainties. Trends in Cell Biology, 2016, 26, 655-667.	7.9	172
106	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology, 2018, 7, e1526250.	4.6	172
107	WNT Signaling in Cancer Immunosurveillance. Trends in Cell Biology, 2019, 29, 44-65.	7.9	168
108	Mitochondrial permeability transition involves dissociation of F ₁ F ₀ ATP synthase dimers and C α ring conformation. EMBO Reports, 2017, 18, 1077-1089.	4.5	163

#	ARTICLE	IF	CITATIONS
109	Methods for Assessing Autophagy and Autophagic Cell Death. <i>Methods in Molecular Biology</i> , 2008, 445, 29-76.	0.9	159
110	Guidelines and recommendations on yeast cell death nomenclature. <i>Microbial Cell</i> , 2018, 5, 4-31.	3.2	158
111	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>Oncolimmunology</i> , 2020, 9, 1703449.	4.6	156
112	Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. <i>Journal of Clinical Investigation</i> , 2011, 121, 1508-1518.	8.2	156
113	Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. <i>EMBO Journal</i> , 2010, 29, 1272-1284.	7.8	155
114	Chloroquine and hydroxychloroquine for cancer therapy. <i>Molecular and Cellular Oncology</i> , 2014, 1, e29911.	0.7	154
115	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e23510.	4.6	153
116	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 1111-1134.	4.6	152
117	Pyroptosis “a cell death modality of its kind?”. <i>European Journal of Immunology</i> , 2010, 40, 627-630.	2.9	150
118	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e25771.	4.6	150
119	Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e452-e463.	10.7	150
120	Mitochondrial control of the NLRP3 inflammasome. <i>Nature Immunology</i> , 2011, 12, 199-200.	14.5	148
121	Trial watch: STING agonists in cancer therapy. <i>Oncolimmunology</i> , 2020, 9, 1777624.	4.6	148
122	Unsaturated fatty acids induce noncanonical autophagy. <i>EMBO Journal</i> , 2015, 34, 1025-1041.	7.8	147
123	Cisplatin Resistance Associated with PARP Hyperactivation. <i>Cancer Research</i> , 2013, 73, 2271-2280.	0.9	143
124	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. <i>Frontiers in Immunology</i> , 2015, 6, 402.	4.8	135
125	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27878.	4.6	134
126	Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 895-902.	3.4	134

#	ARTICLE	IF	CITATIONS
127	Programmed Necrosis. International Review of Cell and Molecular Biology, 2011, 289, 1-35.	3.2	132
128	Trial Watch. Oncoimmunology, 2013, 2, e25238.	4.6	132
129	p53 inhibits autophagy by interacting with the human ortholog of yeast Atg17, RB1CC1/FIP200. Cell Cycle, 2011, 10, 2763-2769.	2.6	131
130	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
131	Immunomodulation by targeted anticancer agents. Cancer Cell, 2021, 39, 310-345.	16.8	131
132	Trial watch. Oncoimmunology, 2013, 2, e23082.	4.6	130
133	Ca2+ Fluxes and Cancer. Molecular Cell, 2020, 78, 1055-1069.	9.7	130
134	The life span-prolonging effect of Sirtuin-1 is mediated by autophagy. Autophagy, 2010, 6, 186-188.	9.1	127
135	Pharmacological modulation of nucleic acid sensors â€” therapeutic potential and persisting obstacles. Nature Reviews Drug Discovery, 2019, 18, 845-867.	46.4	126
136	Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death and Differentiation, 2011, 18, 1403-1413.	11.2	125
137	Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology, 2019, 8, 1638212.	4.6	125
138	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	6.4	122
139	A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Nonâ€”Small Cell Lung Cancer Cells Resistant to Erlotinib. Cancer Research, 2007, 67, 6253-6262.	0.9	121
140	Regulated cell death and adaptive stress responses. Cellular and Molecular Life Sciences, 2016, 73, 2405-2410.	5.4	121
141	Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology, 2018, 7, e1511506.	4.6	121
142	A yeast BH3-only protein mediates the mitochondrial pathway of apoptosis. EMBO Journal, 2011, 30, 2779-2792.	7.8	120
143	Autophagy in hepatic adaptation to stress. Journal of Hepatology, 2020, 72, 183-196.	3.7	120
144	CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy. Cancer Research, 2014, 74, 436-445.	0.9	118

#	ARTICLE	IF	CITATIONS
145	Life, death and burial: multifaceted impact of autophagy. Biochemical Society Transactions, 2008, 36, 786-790.	3.4	117
146	Nonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint. Molecular Cell, 2007, 28, 624-637.	9.7	116
147	Trial watch: TLR3 agonists in cancer therapy. OncoImmunology, 2020, 9, 1771143.	4.6	116
148	Hormesis, cell death and aging. Aging, 2011, 3, 821-828.	3.1	113
149	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. OncoImmunology, 2014, 3, e28473.	4.6	112
150	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
151	Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. Journal of Clinical Investigation, 2021, 131, .	8.2	111
152	Targeting p53 to mitochondria for cancer therapy. Cell Cycle, 2008, 7, 1949-1955.	2.6	110
153	Trial watch. OncoImmunology, 2012, 1, 1557-1576.	4.6	110
154	Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO Journal, 2012, 31, 1055-1057.	7.8	110
155	Oncogene-induced senescence and tumour control in complex biological systems. Cell Death and Differentiation, 2018, 25, 1005-1006.	11.2	110
156	SnapShot: CGAS-STING Signaling. Cell, 2018, 173, 276-276.e1.	28.9	110
157	Autophagy is required for the activation of NF- κ B. Cell Cycle, 2012, 11, 194-199.	2.6	107
158	Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 2016, 128, 3113-3124.	1.4	107
159	Autophagy-dependent ATP release from dying cells via lysosomal exocytosis. Autophagy, 2013, 9, 1624-1625.	9.1	106
160	ATP and cancer immunosurveillance. EMBO Journal, 2021, 40, e108130.	7.8	105
161	Trial watch. OncoImmunology, 2012, 1, 179-188.	4.6	104
162	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. OncoImmunology, 2016, 5, e1088631.	4.6	104

#	ARTICLE	IF	CITATIONS
163	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , 2012, 1, 28-37.	4.6	103
164	Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. <i>Blood</i> , 2008, 111, 2170-2180.	1.4	102
165	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmunology</i> , 2015, 4, e1008814.	4.6	102
166	Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone. <i>Cancer Research</i> , 2008, 68, 5301-5308.	0.9	101
167	Trial Watch. <i>Oncolmunology</i> , 2013, 2, e26621.	4.6	101
168	Targeting post-mitochondrial effectors of apoptosis for neuroprotection. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2009, 1787, 402-413.	1.0	99
169	Immunogenic cell death in radiation therapy. <i>Oncolmunology</i> , 2013, 2, e26536.	4.6	99
170	Trial Watch. <i>Oncolmunology</i> , 2014, 3, e27297.	4.6	99
171	RIP Kinases Initiate Programmed Necrosis. <i>Journal of Molecular Cell Biology</i> , 2009, 1, 8-10.	3.3	98
172	Surface-exposed calreticulin in the interaction between dying cells and phagocytes. <i>Annals of the New York Academy of Sciences</i> , 2010, 1209, 77-82.	3.8	97
173	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmunology</i> , 2015, 4, e974411.	4.6	97
174	Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. <i>Oncolmunology</i> , 2019, 8, e1655964.	4.6	97
175	Adenine nucleotide translocase: a component of the phylogenetically conserved cell death machinery. <i>Cell Death and Differentiation</i> , 2009, 16, 1419-1425.	11.2	96
176	Trial Watch:. <i>Oncolmunology</i> , 2014, 3, e28694.	4.6	95
177	eIF2 γ phosphorylation as a biomarker of immunogenic cell death. <i>Seminars in Cancer Biology</i> , 2015, 33, 86-92.	9.6	95
178	Non-apoptotic functions of apoptosis-regulatory proteins. <i>EMBO Reports</i> , 2012, 13, 322-330.	4.5	92
179	Trial watch. <i>Oncolmunology</i> , 2013, 2, e23803.	4.6	92
180	Trial watch. <i>Oncolmunology</i> , 2013, 2, e22789.	4.6	92

#	ARTICLE	IF	CITATIONS
181	Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. <i>Cell Cycle</i> , 2012, 11, 3851-3860.	2.6	91
182	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmunology</i> , 2020, 9, 1777625.	4.6	91
183	Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. <i>Autophagy</i> , 2012, 8, 413-415.	9.1	90
184	Disruption of the hexokinase-VDAC complex for tumor therapy. <i>Oncogene</i> , 2008, 27, 4633-4635.	5.9	89
185	Anticancer activity of cardiac glycosides. <i>Oncolmunology</i> , 2012, 1, 1640-1642.	4.6	89
186	Trial Watch- Oncolytic viruses and cancer therapy. <i>Oncolmunology</i> , 2016, 5, e1117740.	4.6	88
187	Mitochondrial regulation of cell death: a phylogenetically conserved control. <i>Microbial Cell</i> , 2016, 3, 101-108.	3.2	87
188	Trial watch: Dendritic cell-based anticancer immunotherapy. <i>Oncolmunology</i> , 2017, 6, e1328341.	4.6	87
189	Oncosuppressive Functions of Autophagy. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 2251-2269.	5.4	86
190	Trial Watch. <i>Oncolmunology</i> , 2012, 1, 493-506.	4.6	86
191	Immunomodulation by anticancer cell cycle inhibitors. <i>Nature Reviews Immunology</i> , 2020, 20, 669-679.	22.7	86
192	Inhibition of autophagy by TAB2 and TAB3. <i>EMBO Journal</i> , 2011, 30, 4908-4920.	7.8	85
193	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	84
194	Trial Watch. <i>Oncolmunology</i> , 2013, 2, e25595.	4.6	83
195	Mitochondrial apoptosis without VDAC. <i>Nature Cell Biology</i> , 2007, 9, 487-489.	10.3	79
196	PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. <i>Oncolmunology</i> , 2020, 9, 1721810.	4.6	79
197	Akt-mediated phosphorylation of MICU 1 regulates mitochondrial Ca^{2+} levels and tumor growth. <i>EMBO Journal</i> , 2019, 38, .	7.8	77
198	Mitochondrial control of cell death induced by hyperosmotic stress. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 3-18.	4.9	76

#	ARTICLE	IF	CITATIONS
199	Trial Watch. OncoImmunology, 2014, 3, e29179.	4.6	76
200	Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nature Reviews Clinical Oncology, 2022, 19, 114-131.	27.6	76
201	Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy. Cancer Journal (Sudbury, Mass), 2011, 17, 351-358.	2.0	75
202	ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. OncoImmunology, 2013, 2, e24568.	4.6	75
203	TP53 and MTOR crosstalk to regulate cellular senescence. Aging, 2010, 2, 535-537.	3.1	75
204	Immune recognition of irradiated cancer cells. Immunological Reviews, 2017, 280, 220-230.	6.0	73
205	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
206	Functions of BCL-X _L at the Interface between Cell Death and Metabolism. International Journal of Cell Biology, 2013, 2013, 1-10.	2.5	71
207	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 4820-4831.	7.0	71
208	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	12.8	71
209	Trial Watch. OncoImmunology, 2012, 1, 306-315.	4.6	70
210	Noncanonical Cell Fate Regulation by Bcl-2 Proteins. Trends in Cell Biology, 2020, 30, 537-555.	7.9	70
211	Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy, 2012, 8, 1175-1184.	9.1	69
212	Trial Watch. OncoImmunology, 2014, 3, e27048.	4.6	69
213	Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway. PLoS ONE, 2007, 2, e1337.	2.5	67
214	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology, 2018, 7, e1503032.	4.6	67
215	Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. Cell Metabolism, 2019, 30, 754-767.e9.	16.2	67
216	Mitochondrial Liaisons of p53. Antioxidants and Redox Signaling, 2011, 15, 1691-1714.	5.4	66

#	ARTICLE	IF	CITATIONS
217	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. , 2019, 7, 27.		66
218	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	7.9	66
219	MLKL regulates necrotic plasma membrane permeabilization. Cell Research, 2014, 24, 139-140.	12.0	65
220	Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy. Oncogene, 2012, 31, 2805-2808.	5.9	64
221	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	4.6	64
222	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
223	Modeling Tumor Immunology and Immunotherapy in Mice. Trends in Cancer, 2018, 4, 599-601.	7.4	63
224	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. OncoImmunology, 2020, 9, 1796002.	4.6	63
225	Trial watch: Dendritic cell-based anticancer therapy. OncoImmunology, 2014, 3, e963424.	4.6	62
226	Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. OncoImmunology, 2015, 4, e1058597.	4.6	62
227	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	4.6	62
228	Viral subversion of immunogenic cell death. Cell Cycle, 2009, 8, 860-869.	2.6	60
229	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. OncoImmunology, 2017, 6, e1363139.	4.6	60
230	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. , 2020, 8, e000979.		60
231	Trial Watch. OncoImmunology, 2013, 2, e24238.	4.6	58
232	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery, 2022, 21, 440-462.	46.4	58
233	Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle, 2011, 10, 2323-2330.	2.6	57
234	Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene, 2012, 31, 3536-3546.	5.9	57

#	ARTICLE	IF	CITATIONS
235	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Science Alliance, 2021, 4, e202000955.	2.8	56
236	Fighting Resilient Cancers with Iron. Trends in Cell Biology, 2018, 28, 77-78.	7.9	55
237	Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death and Disease, 2019, 10, 578.	6.3	54
238	Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene, 2009, 28, 2205-2218.	5.9	53
239	Viral strategies for the evasion of immunogenic cell death. Journal of Internal Medicine, 2010, 267, 526-542.	6.0	53
240	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget, 2017, 8, 3197-3205.	1.8	53
241	Trial Watch”Immunostimulation with cytokines in cancer therapy. Oncoimmunology, 2016, 5, e1115942.	4.6	52
242	Autophagy in natural and therapy-driven anticancer immunosurveillance. Autophagy, 2017, 13, 2163-2170.	9.1	52
243	Trial watch: dietary interventions for cancer therapy. Oncoimmunology, 2019, 8, e1591878.	4.6	52
244	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. , 2019, 7, 312.		52
245	Trial watch. Oncoimmunology, 2014, 3, e29030.	4.6	51
246	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. Seminars in Cancer Biology, 2018, 52, 125-134.	9.6	51
247	Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle, 2012, 11, 4079-4092.	2.6	50
248	Immunosurveillance as a regulator of tissue homeostasis. Trends in Immunology, 2013, 34, 471-481.	6.8	50
249	Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology, 2013, 2, e26494.	4.6	50
250	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. Journal of Molecular Diagnostics, 2018, 20, 95-109.	2.8	50
251	Trial Watch. Oncoimmunology, 2013, 2, e24850.	4.6	49
252	Defective autophagy control by the p53 rheostat in cancer. Cell Cycle, 2010, 9, 250-255.	2.6	48

#	ARTICLE	IF	CITATIONS
253	Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. <i>Autophagy</i> , 2013, 9, 415-417.	9.1	48
254	Selective killing of p53-deficient cancer cells by SP600125. <i>EMBO Molecular Medicine</i> , 2012, 4, 500-514.	6.9	47
255	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolimmunology</i> , 2015, 4, e985940.	4.6	47
256	Targeting HSP70 for Cancer Therapy. <i>Molecular Cell</i> , 2009, 36, 176-177.	9.7	46
257	IKK connects autophagy to major stress pathways. <i>Autophagy</i> , 2010, 6, 189-191.	9.1	46
258	Cell Death Signaling and Anticancer Therapy. <i>Frontiers in Oncology</i> , 2011, 1, 5.	2.8	46
259	Trial Watch"Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolimmunology</i> , 2016, 5, e1149674.	4.6	46
260	Autophagy in the cancer-immunity dialogue. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 40-50.	13.7	46
261	Victories and deceptions in tumor immunology. <i>Oncolimmunology</i> , 2013, 2, e23687.	4.6	43
262	Mechanisms of p53-mediated mitochondrial membrane permeabilization. <i>Cell Research</i> , 2008, 18, 708-710.	12.0	42
263	Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. <i>Cell Cycle</i> , 2008, 7, 1956-1961.	2.6	41
264	Autophagy Mediates Tumor Suppression via Cellular Senescence. <i>Trends in Cell Biology</i> , 2016, 26, 1-3.	7.9	41
265	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1855-1863.	7.0	41
266	Trial Watch: Radioimmunotherapy for oncological indications. <i>Oncolimmunology</i> , 2014, 3, e954929.	4.6	40
267	EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D ₃ in acute myeloid leukemia cells. <i>Cell Cycle</i> , 2013, 12, 2978-2991.	2.6	39
268	p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. <i>Cell Cycle</i> , 2009, 8, 1380-1385.	2.6	38
269	Disruption of the PP1/GADD34 complex induces calreticulin exposure. <i>Cell Cycle</i> , 2009, 8, 3971-3977.	2.6	38
270	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1433982.	4.6	38

#	ARTICLE	IF	CITATIONS
271	An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe. <i>Cell Death and Disease</i> , 2010, 1, e25-e25.	6.3	37
272	Loss-of-function alleles of <i>P2RX7</i> and <i>TLR4</i> fail to affect the response to chemotherapy in non-small cell lung cancer. <i>Oncolmunology</i> , 2012, 1, 271-278.	4.6	36
273	Immunosurveillance against tetraploidization-induced colon tumorigenesis. <i>Cell Cycle</i> , 2013, 12, 473-479.	2.6	36
274	Trial Watch. <i>Oncolmunology</i> , 2014, 3, e28185.	4.6	36
275	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. <i>Oncolmunology</i> , 2017, 6, e1371896.	4.6	36
276	Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α -Ketoglutarate. <i>Cell Reports</i> , 2019, 27, 820-834.e9.	6.4	36
277	Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. <i>Oncolmunology</i> , 2014, 3, e27663.	4.6	35
278	Impact of myeloid cells on the efficacy of anticancer chemotherapy. <i>Current Opinion in Immunology</i> , 2014, 30, 24-31.	5.5	35
279	Whole Cell Strategies Based on lux Genes for High Throughput Applications Toward New Antimicrobials. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2006, 9, 501-514.	1.1	34
280	Longevity-relevant regulation of autophagy at the level of the acetylproteome. <i>Autophagy</i> , 2011, 7, 647-649.	9.1	34
281	Preferential killing of p53-deficient cancer cells by reversine. <i>Cell Cycle</i> , 2012, 11, 2149-2158.	2.6	34
282	Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. <i>Oncolmunology</i> , 2020, 9, 1830524.	4.6	34
283	Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. <i>Cell Cycle</i> , 2011, 10, 3168-3175.	2.6	33
284	Antiapoptotic activity of argon and xenon. <i>Cell Cycle</i> , 2013, 12, 2636-2642.	2.6	33
285	Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides. <i>Trends in Cancer</i> , 2021, 7, 557-572.	7.4	33
286	Independent transcriptional reprogramming and apoptosis induction by cisplatin. <i>Cell Cycle</i> , 2012, 11, 3472-3480.	2.6	32
287	Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. <i>Haematologica</i> , 2020, 105, 1868-1878.	3.5	32
288	Myeloid-Derived Suppressor Cells and Radiotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 545-557.	3.4	32

#	ARTICLE	IF	CITATIONS
289	A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 182-190.	4.9	31
290	Direct molecular interactions between Beclin 1 and the canonical NF κ B activation pathway. Autophagy, 2012, 8, 268-270.	9.1	31
291	Trial Watch. Oncolmunology, 2014, 3, e28344.	4.6	31
292	Trial watch: intratumoral immunotherapy. Oncolmunology, 2021, 10, 1984677.	4.6	31
293	Trial watch: DNA-based vaccines for oncological indications. Oncolmunology, 2017, 6, e1398878.	4.6	30
294	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. Oncolmunology, 2021, 10, 1962592.	4.6	30
295	Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery. Immunity, 2021, 54, 721-736.e10.	14.3	30
296	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30
297	Trial Watch: Adoptive cell transfer for oncological indications. Oncolmunology, 2015, 4, e1046673.	4.6	29
298	Intracellular redox equilibrium and growth phase affect the performance of luciferase-based biosensors. Journal of Biotechnology, 2007, 127, 188-198.	3.8	28
299	Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison. Biochemical Pharmacology, 2008, 76, 1417-1425.	4.4	28
300	Autophagy and innate immunity ally against bacterial invasion. EMBO Journal, 2011, 30, 3213-3214.	7.8	28
301	Karyotypic Aberrations in Oncogenesis and Cancer Therapy. Trends in Cancer, 2015, 1, 124-135.	7.4	28
302	Chapter Eighteen Methods to Dissect Mitochondrial Membrane Permeabilization in the Course of Apoptosis. Methods in Enzymology, 2008, 442, 355-374.	1.0	27
303	Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncolmunology, 2014, 3, e967147.	4.6	27
304	Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate <i>in vivo</i> . Cell Cycle, 2015, 14, 2399-2407.	2.6	27
305	Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark. Oncolmunology, 2015, 4, e1058037.	4.6	27
306	Apaf-1 Deficiency Causes Chromosomal Instability. Cell Cycle, 2007, 6, 3103-3107.	2.6	26

#	ARTICLE	IF	CITATIONS
307	Current trends of anticancer immunochemotherapy. <i>Oncolmmunology</i> , 2013, 2, e25396.	4.6	26
308	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. <i>Cell Cycle</i> , 2013, 12, 417-421.	2.6	26
309	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	4.6	26
310	Secondary Necrosis: Accidental No More. <i>Trends in Cancer</i> , 2017, 3, 1-2.	7.4	26
311	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	7.0	26
312	Control of host mitochondria by bacterial pathogens. <i>Trends in Microbiology</i> , 2022, 30, 452-465.	7.7	25
313	Shigella Targets the Mitochondrial Checkpoint of Programmed Necrosis. <i>Cell Host and Microbe</i> , 2009, 5, 107-109.	11.0	24
314	Drugging cancer metabolism: Expectations vs. reality. <i>International Review of Cell and Molecular Biology</i> , 2019, 347, 1-26.	3.2	24
315	Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. <i>Oncolmmunology</i> , 2013, 2, e24786.	4.6	23
316	Mitochondrial control of innate immune signaling by irradiated cancer cells. <i>Oncolmmunology</i> , 2020, 9, 1797292.	4.6	23
317	Stress responses in stromal cells and tumor homeostasis. , 2019, 200, 55-68.		22
318	Defective Autophagy Initiates Malignant Transformation. <i>Molecular Cell</i> , 2016, 62, 473-474.	9.7	21
319	Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. <i>Oncolmmunology</i> , 2017, 6, e1346766.	4.6	21
320	BAX and BAK at the Gates of Innate Immunity. <i>Trends in Cell Biology</i> , 2018, 28, 343-345.	7.9	21
321	TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. <i>Oncolmmunology</i> , 2021, 10, 1889822.	4.6	21
322	A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients. <i>Cell Reports</i> , 2021, 35, 108983.	6.4	21
323	Past, Present, and Future of Molecular and Cellular Oncology. <i>Frontiers in Oncology</i> , 2011, 1, 1.	2.8	20
324	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. <i>Oncolmmunology</i> , 2013, 2, e22409.	4.6	20

#	ARTICLE	IF	CITATIONS
325	High-Throughput Quantification of GFP-LC3+ Dots by Automated Fluorescence Microscopy. <i>Methods in Enzymology</i> , 2017, 587, 71-86.	1.0	20
326	Novel insights into the mitochondrial permeability transition. <i>Cell Cycle</i> , 2014, 13, 2666-2670.	2.6	19
327	Apoptotic caspases cut down the immunogenicity of radiation. <i>Oncolmunology</i> , 2019, 8, e1655364.	4.6	19
328	Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents. <i>Oncolmunology</i> , 2021, 10, 1889101.	4.6	19
329	BAX and BAK dynamics control mitochondrial DNA release during apoptosis. <i>Cell Death and Differentiation</i> , 2022, 29, 1296-1298.	11.2	19
330	Trial Watch: Proteasomal inhibitors for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2015, 2, e974463.	0.7	18
331	TREX1 Cuts Down on Cancer Immunogenicity. <i>Trends in Cell Biology</i> , 2017, 27, 543-545.	7.9	18
332	Immunological effects of chemotherapy in spontaneous breast cancers. <i>Oncolmunology</i> , 2013, 2, e27158.	4.6	17
333	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. <i>Gynecologic Oncology</i> , 2021, 162, 652-660.	1.4	17
334	Prognostic value of LIPC in non-small cell lung carcinoma. <i>Cell Cycle</i> , 2013, 12, 647-654.	2.6	16
335	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. <i>Oncolmunology</i> , 2014, 3, e955685.	4.6	16
336	Potent immunosuppressive effects of the oncometabolite <i>R</i> -2-hydroxyglutarate. <i>Oncolmunology</i> , 2018, 7, e1528815.	4.6	16
337	Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 14.	3.0	16
338	Calreticulin arms NK cells against leukemia. <i>Oncolmunology</i> , 2020, 9, 1671763.	4.6	16
339	Quantification of cellular viability by automated microscopy and flow cytometry. <i>Oncotarget</i> , 2015, 6, 9467-9475.	1.8	16
340	Metabolic enzymes expressed by cancer cells impact the immune infiltrate. <i>Oncolmunology</i> , 2019, 8, e1571389.	4.6	15
341	Evaluation of Rapamycin-Induced Cell Death. <i>Methods in Molecular Biology</i> , 2012, 821, 125-169.	0.9	15
342	NF- κ B blockade upregulates Bax, TSP-1, and TSP-2 expression in rat granulation tissue. <i>Journal of Molecular Medicine</i> , 2009, 87, 481-492.	3.9	14

#	ARTICLE	IF	CITATIONS
343	Necroptosis Turns TNF Lethal. <i>Immunity</i> , 2011, 35, 849-851.	14.3	14
344	Mitochondrial Dynamics: A Strategy for Avoiding Autophagy. <i>Current Biology</i> , 2011, 21, R478-R480.	3.9	14
345	PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. <i>Oncolmunology</i> , 2018, 7, e1460298.	4.6	14
346	Unexpected role of the phosphate carrier in mitochondrial fragmentation. <i>Cell Death and Differentiation</i> , 2008, 15, 616-618.	11.2	13
347	Bacterial Invasion: Linking Autophagy and Innate Immunity. <i>Current Biology</i> , 2010, 20, R106-R108.	3.9	13
348	Reverse Warburg: Straight to cancer. <i>Cell Cycle</i> , 2012, 11, 1059-1059.	2.6	13
349	Immunosuppressive cell death in cancer. <i>Nature Reviews Immunology</i> , 2017, 17, 402-402.	22.7	13
350	Lysosome-targeting agents in cancer therapy. <i>Oncotarget</i> , 2017, 8, 112168-112169.	1.8	13
351	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. <i>Trends in Cancer</i> , 2022, 8, 426-444.	7.4	13
352	A real-time analysis of QacR-regulated multidrug resistance in <i>Staphylococcus aureus</i> . <i>Biochemical and Biophysical Research Communications</i> , 2003, 301, 24-30.	2.1	12
353	Fluorescent Biosensors for the Detection of HMGB1 Release. <i>Methods in Molecular Biology</i> , 2013, 1004, 43-56.	0.9	12
354	Novel insights into the mechanism of action of lenalidomide. <i>Oncolmunology</i> , 2014, 3, e28386.	4.6	12
355	Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. <i>Oncolmunology</i> , 2015, 4, e1008853.	4.6	12
356	STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. <i>Oncolmunology</i> , 2016, 5, e1126063.	4.6	12
357	Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. <i>Oncotarget</i> , 2017, 8, 5686-5691.	1.8	12
358	Immune effectors required for the therapeutic activity of vorinostat. <i>Oncolmunology</i> , 2013, 2, e27157.	4.6	11
359	Cancer immunotherapy turns viral. <i>Oncolmunology</i> , 2013, 2, e24802.	4.6	11
360	New immunotherapeutic paradigms for castration-resistant prostate cancer. <i>Oncolmunology</i> , 2013, 2, e26084.	4.6	11

#	ARTICLE	IF	CITATIONS
361	Immunosuppressive β T cells foster pancreatic carcinogenesis. <i>Onc Immunology</i> , 2016, 5, e1237328.	4.6	11
362	Immunogenicity of cell death driven by immune effectors. , 2020, 8, e000802.		11
363	Amplified Detection of Transcriptional and Translational Inhibitors in Bioluminescent <i>Escherichia Coli</i> K-12. <i>Journal of Biomolecular Screening</i> , 2003, 8, 340-346.	2.6	10
364	Cytofluorometric Assessment of Cell Cycle Progression. <i>Methods in Molecular Biology</i> , 2013, 965, 93-120.	0.9	10
365	Calreticulin and type I interferon: An unsuspected connection. <i>Onc Immunology</i> , 2017, 6, e1288334.	4.6	10
366	Possible mechanisms of cancer prevention by nicotinamide. <i>British Journal of Pharmacology</i> , 2021, 178, 2034-2040.	5.4	10
367	Immunology of Cell Death in Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1208.	4.1	10
368	Targeting Serine in Cancer: Is Two Better Than One?. <i>Trends in Cancer</i> , 2021, 7, 668-670.	7.4	10
369	Immunogenic Cell Death Driven by Radiationâ€™Impact on the Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, 180, 281-296.	0.5	10
370	Immunosurveillance against cancer-associated hyperploidy. <i>Oncotarget</i> , 2012, 3, 1270-1271.	1.8	10
371	FADD: an endogenous inhibitor of RIP3-driven regulated necrosis. <i>Cell Research</i> , 2011, 21, 1383-1385.	12.0	9
372	Doubling the blockade for melanoma immunotherapy. <i>Onc Immunology</i> , 2016, 5, e1106127.	4.6	9
373	Heavy Metal to Rock the Immune Infiltrate. <i>Trends in Immunology</i> , 2017, 38, 539-541.	6.8	9
374	Cancer Cells Thrive on Stress. <i>Trends in Cell Biology</i> , 2019, 29, 447-449.	7.9	9
375	Involvement of p38 β in the mitotic progression of <i>p53</i> ^{-/-} tetraploid cells. <i>Cell Cycle</i> , 2010, 9, 2895-2901.	2.6	8
376	Common and divergent functions of Beclin 1 and Beclin 2. <i>Cell Research</i> , 2013, 23, 1341-1342.	12.0	8
377	NK cells beat T cells at early breast cancer control. <i>Onc Immunology</i> , 2020, 9, 1806010.	4.6	8
378	A new role for cytoplasmic p53: Binding and destroying double-stranded RNA. <i>Cell Cycle</i> , 2010, 9, 2491-2501.	2.6	7

#	ARTICLE	IF	CITATIONS
379	Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. <i>Annals of the New York Academy of Sciences</i> , 2013, 1284, 57-61.	3.8	7
380	Mitophagy: Permitted by Prohibitin. <i>Current Biology</i> , 2017, 27, R73-R76.	3.9	7
381	CARs on a highway with roadblocks. <i>Oncolmunology</i> , 2017, 6, e1388486.	4.6	7
382	Using epigenetic modifiers to target cancer stem cell immunoevasion. <i>Cancer Cell</i> , 2021, 39, 1573-1575.	16.8	7
383	Nutlin kills cancer cells via mitochondrial p53. <i>Cell Cycle</i> , 2009, 8, 1645-1648.	2.6	6
384	Novel multifunctional antibody approved for the treatment of breast cancer. <i>Oncolmunology</i> , 2013, 2, e24567.	4.6	6
385	Assessment of Glycolytic Flux and Mitochondrial Respiration in the Course of Autophagic Responses. <i>Methods in Enzymology</i> , 2017, 588, 155-170.	1.0	6
386	The complement system is also important in immunogenic cell death. <i>Nature Reviews Immunology</i> , 2017, 17, 143-143.	22.7	6
387	Autophagy Mediates the Metabolic Benefits of Endurance Training. <i>Circulation Research</i> , 2012, 110, 1276-1278.	4.5	5
388	Transgenerational cell fate profiling. <i>Cell Cycle</i> , 2013, 12, 183-190.	2.6	5
389	Preface. <i>Methods in Enzymology</i> , 2014, 542, xix-xxiii.	1.0	5
390	Novel Insights into PML-Dependent Oncosuppression. <i>Trends in Cell Biology</i> , 2016, 26, 889-890.	7.9	5
391	Blinatumomab bridges the gap between leukemia and immunity. <i>Oncolmunology</i> , 2017, 6, e1358335.	4.6	5
392	PD-L1 blockade for urothelial carcinoma. <i>Oncolmunology</i> , 2017, 6, e1334028.	4.6	5
393	Driving to Cancer on a Four-Lane Expressway. <i>Trends in Genetics</i> , 2017, 33, 491-492.	6.7	5
394	Transient Autophagy Inhibition Precipitates Oncogenesis: A Red Flag For Pharmacological Autophagy Inhibitors?. <i>Trends in Cell Biology</i> , 2020, 30, 339-340.	7.9	5
395	MPA/DMBA-driven mammary carcinomas. <i>Methods in Cell Biology</i> , 2021, 163, 1-19.	1.1	5
396	Immunological barriers to immunotherapy in primary and metastatic breast cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e14393.	6.9	5

#	ARTICLE	IF	CITATIONS
397	Methods to Detect Immunogenic Cell Death In Vivo. Methods in Molecular Biology, 2020, 2055, 433-452.	0.9	5
398	Cytofluorometric Purification of Diploid and Tetraploid Cancer Cells. Methods in Molecular Biology, 2011, 761, 47-63.	0.9	5
399	Preface: Endoplasmic reticulum in health and disease. International Review of Cell and Molecular Biology, 2020, 350, xiii-xvii.	3.2	5
400	Senescence Inflames the Pancreatic Tumor Microenvironment. Cell Reports Medicine, 2020, 1, 100020.	6.5	5
401	Immunostimulatory effects of radioimmunotherapy. , 2022, 10, e004403.		5
402	Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence. OncoImmunology, 2022, 11, 2052411.	4.6	5
403	Catastrophic DNA replication in unscheduled tetraploid cells. Trends in Genetics, 2022, 38, 787-788.	6.7	5
404	Rejuvenated T cells attack old tumors. OncoImmunology, 2013, 2, e24103.	4.6	4
405	Molecular Regulation of Circadian Rhythms by Polyamines. Cell Metabolism, 2015, 22, 757-758.	16.2	4
406	Detection of Apoptotic Versus Autophagic Cell Death by Flow Cytometry. Methods in Molecular Biology, 2016, 1419, 1-16.	0.9	4
407	Aberrant ketolysis fuels hepatocellular cancer progression. Cell Research, 2016, 26, 1077-1078.	12.0	4
408	Etiological involvement of CFTR in apparently unrelated human diseases. Molecular and Cellular Oncology, 2019, 6, 1558874.	0.7	4
409	Chromatin and genomic instability in cancer. International Review of Cell and Molecular Biology, 2021, 364, ix-xvii.	3.2	4
410	Defective autophagy gets to the brain. Oncotarget, 2015, 6, 39396-39397.	1.8	4
411	MDSCs sneak CSCs out of (immuno)surveillance. Trends in Immunology, 2022, 43, 1-3.	6.8	4
412	Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models. Molecular Therapy - Nucleic Acids, 2022, 29, 189-203.	5.1	4
413	Discarding multidrug resistance inducers, the possible role of a biosensing reporter in antimicrobial discovery. Luminescence, 2004, 19, 225-227.	2.9	3
414	Preface. Methods in Enzymology, 2014, 543, xv-xix.	1.0	3

#	ARTICLE	IF	CITATIONS
415	A four-lane highway to cancer. <i>Nature Reviews Molecular Cell Biology</i> , 2016, 17, 398-398.	37.0	3
416	CD103 ⁺ cells at the forefront of anticancer immunity. <i>Oncolmunology</i> , 2017, 6, e1356154.	4.6	3
417	Everybody In! No Bouncers at Tumor Gates. <i>Trends in Genetics</i> , 2018, 34, 85-87.	6.7	3
418	T Cells: Friends and Foes. <i>International Review of Cell and Molecular Biology</i> , 2019, 342, xi-xiv.	3.2	3
419	Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity. <i>International Review of Cell and Molecular Biology</i> , 2019, 344, xi-xv.	3.2	3
420	Targeting Mutant KRAS for Immunogenic Cell Death Induction. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 1-3.	8.7	3
421	Preface“Autophagy: An old mechanism with new challenges ahead. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 172, xv-xix.	1.7	3
422	Ketosis versus carbotoxicity “metabolism determines the outcome of cancer immunotherapy. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1868266.	0.7	3
423	Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells. <i>STAR Protocols</i> , 2021, 2, 100488.	1.2	3
424	A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients. <i>Oncolmunology</i> , 2022, 11, 2059878.	4.6	3
425	An epigenetic modifier triggers therapeutic immune responses against breast cancer. <i>Oncolmunology</i> , 2017, 6, e1313376.	4.6	2
426	Preface“Dendritic cells: Master regulators of innate and adaptive immunity. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, ix-xiv.	3.2	2
427	Born to Kill: NK Cells Go to War against Cancer. <i>Trends in Cancer</i> , 2019, 5, 143-145.	7.4	2
428	Monitoring abscopal responses to radiation in mice. <i>Methods in Enzymology</i> , 2020, 635, 111-125.	1.0	2
429	Pathophysiology of Cancer Cell Death. , 2020, , 74-83.e4.		2
430	Could Protons Promote Tumor Control by Avoiding Lymphopenia?. <i>Journal of Thoracic Oncology</i> , 2021, 16, e39-e41.	1.1	2
431	Pathophysiology of Cancer Cell Death. , 2014, , 69-77.e3.		2
432	Amino acid deprivation promotes intestinal homeostasis through autophagy. <i>Oncotarget</i> , 2016, 7, 29877-29878.	1.8	2

#	ARTICLE	IF	CITATIONS
433	Mitochondrial DNA Drives Abscopal Responses to Radiation that are Inhibited by Autophagy. SSRN Electronic Journal, 0, , .	0.4	2
434	Heterogeneous cellular effects of α -ketoglutarate esters. Aging, 2019, 11, 3412-3413.	3.1	2
435	Cytofluorometric assessment of cell cycle progression in irradiated cells. Methods in Cell Biology, 2022, , 1-16.	1.1	2
436	Viperin Turns Coat in Cytomegalovirus Infection. Developmental Cell, 2011, 20, 737-738.	7.0	1
437	Cytofluorometric Quantification of Cell Death Elicited by NLR Proteins. Methods in Molecular Biology, 2016, 1417, 231-245.	0.9	1
438	Novel immune checkpoint blocker to treat Merkel cell carcinoma. OncoImmunology, 2017, 6, e1315496.	4.6	1
439	T Cells: Friends and Foes. International Review of Cell and Molecular Biology, 2018, 341, ix-xii.	3.2	1
440	Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients. OncoImmunology, 2019, 8, 1606624.	4.6	1
441	Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity. International Review of Cell and Molecular Biology, 2019, 345, ix-xiii.	3.2	1
442	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl.	1.0	1
443	Preface: Dendritic cells: Master regulators of innate and adaptive immunity. International Review of Cell and Molecular Biology, 2019, 349, xi-xvi.	3.2	1
444	Preface: Life through deathâ€”Key role of cellular suicide for colonial and organismal homeostasis. International Review of Cell and Molecular Biology, 2020, 353, ix-xiii.	3.2	1
445	Preface: Life through deathâ€”Key role of cellular suicide for colonial and organismal homeostasis. International Review of Cell and Molecular Biology, 2020, 352, xi-xv.	3.2	1
446	Cancer Immunotherapy with CDK7 Inhibitors. Trends in Cancer, 2020, 6, 361-363.	7.4	1
447	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 631, xxiii-xxlii.	1.0	1
448	Ca ²⁺ in health and disease. International Review of Cell and Molecular Biology, 2021, 363, ix-xv.	3.2	1
449	Canonical versus noncanonical autophagy. , 2021, , 1-8.		1
450	Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy. Trends in Cancer, 2021, 7, 179-181.	7.4	1

#	ARTICLE	IF	CITATIONS
451	Targeting replication stress to tackle cancer stem cells. Cell Death and Disease, 2021, 12, 315.	6.3	1
452	Vesicular trafficking in cellular responses to stress. Methods in Cell Biology, 2021, 164, xvii-xxi.	1.1	1
453	Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents. Blood, 2021, 138, 2406-2406.	1.4	1
454	Restored Ketosis Drives Anticancer Immunity in Colorectal Cancer. Cancer Research, 2022, 82, 1464-1466.	0.9	1
455	The Grand Challenges to Cellular and Molecular Oncology. Frontiers in Oncology, 2011, 1, 2.	2.8	0
456	Nonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint. Molecular Cell, 2012, 48, 322-324.	9.7	0
457	Quantification of Cell Cycle-Arresting Proteins. Methods in Molecular Biology, 2013, 965, 121-142.	0.9	0
458	Metabolomic Profiling of Cultured Cancer Cells. Methods in Enzymology, 2014, 543, 165-178.	1.0	0
459	Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. Clinical Cancer Research, 2019, 25, 6890-6892.	7.0	0
460	Caspase 2 and p53 Reunited in Tumor Control. Trends in Cell Biology, 2020, 30, 917-918.	7.9	0
461	Preface " Extracellular vesicles: An exciting and rapidly expanding field of investigation. Methods in Enzymology, 2020, 645, xv-xviii.	1.0	0
462	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 635, xix-xxxviii.	1.0	0
463	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 636, xvii-xxxvi.	1.0	0
464	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 632, xxiii-xlii.	1.0	0
465	Preface: Ca ²⁺ in health and disease. International Review of Cell and Molecular Biology, 2021, 362, xi-xvii.	3.2	0
466	Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons. Methods in Cell Biology, 2021, 163, xvii-xxv.	1.1	0
467	Oncosuppressive functions of PIDD1 in response to centrosome amplification. Cell Death and Disease, 2021, 12, 175.	6.3	0
468	Abstract PO-036: Immunological characterization of mouse HR+ mammary tumors relapsing after radiation therapy. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
469	Vesicular trafficking in cellular responses to stress. <i>Methods in Cell Biology</i> , 2021, 165, xix-xxiii.	1.1	0
470	The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML. <i>Blood</i> , 2007, 110, 399-399.	1.4	0
471	Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives. <i>International Review of Cell and Molecular Biology</i> , 2021, 365, ix-xx.	3.2	0
472	Preface: Life through deathâ€”Key role of cellular suicide for colonial and organismal homeostasis. <i>International Review of Cell and Molecular Biology</i> , 2020, 351, xi-xv.	3.2	0
473	Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma. <i>Trends in Cancer</i> , 2021, , .	7.4	0
474	Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, ix-xx.	3.2	0
475	Cytofluorometric assessment of acute cell death responses driven by radiation therapy. <i>Methods in Cell Biology</i> , 2022, , .	1.1	0
476	RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. <i>Methods in Cell Biology</i> , 2022, , .	1.1	0